A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC

BACKGROUND: Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a potentially low risk of injection site reactions (ISRs) and promising antiemetic efficacy in patients receiving cisplatin‐based highly emetogenic chemotherapy in a prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuura, Kazuo, Tsurutani, Junji, Inoue, Kenichi, Tanabe, Yuko, Taira, Tetsuhiko, Kubota, Kaoru, Tamura, Tomohide, Saeki, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306508/
https://www.ncbi.nlm.nih.gov/pubmed/35045185
http://dx.doi.org/10.1002/cncr.34088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306508/
https://www.ncbi.nlm.nih.gov/pubmed/35045185
http://dx.doi.org/10.1002/cncr.34088

Ejemplares similares